229 related articles for article (PubMed ID: 33685566)
1. Analysis of the long-term efficacy and safety of subcutaneous immunotherapy for atopic dermatitis.
Zhou J; Chen S; Song Z
Allergy Asthma Proc; 2021 Mar; 42(2):e47-e54. PubMed ID: 33685566
[No Abstract] [Full Text] [Related]
2. Subcutaneous Immunotherapy for Allergic Asthma in a Single Center of Korea: Efficacy, Safety, and Clinical Response Predictors.
Lee JH; Kim SC; Choi H; Jung CG; Ban GY; Shin YS; Nahm DH; Park HS; Ye YM
J Korean Med Sci; 2017 Jul; 32(7):1124-1130. PubMed ID: 28581269
[TBL] [Abstract][Full Text] [Related]
3. Clinical improvement and immunological changes in atopic dermatitis patients undergoing subcutaneous immunotherapy with a house dust mite allergoid: a pilot study.
Bussmann C; Maintz L; Hart J; Allam JP; Vrtala S; Chen KW; Bieber T; Thomas WR; Valenta R; Zuberbier T; Sager A; Novak N
Clin Exp Allergy; 2007 Sep; 37(9):1277-85. PubMed ID: 17845407
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy comparison and safety analysis of subcutaneous specific immunotherapy with standardized house dust mite allergen in patients with single and multiple allergic rhinitis].
Huang HH; Xu C; Liu L; Chai RN
Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Jun; 56(6):774-783. PubMed ID: 35785859
[No Abstract] [Full Text] [Related]
5. Clinical Efficacy of Subcutaneous Allergen Immunotherapy in Patients with Atopic Dermatitis.
Nahm DH; Kim ME; Kwon B; Cho SM; Ahn A
Yonsei Med J; 2016 Nov; 57(6):1420-6. PubMed ID: 27593870
[TBL] [Abstract][Full Text] [Related]
6. Aqueous intradermal low-dose house dust mite immunotherapy in tropical settings: a valid cost-effective approach for developing nations?
Rondon C; Sánchez-Borges M; Cupello ER; Fabiano F; Capriles-Hulett A
Allergol Immunopathol (Madr); 2021; 49(2):31-39. PubMed ID: 33641291
[TBL] [Abstract][Full Text] [Related]
7. CC chemokines as potential immunologic markers correlated with clinical improvement of atopic dermatitis patients by immunotherapy.
Kwon YS; Oh SH; Wu WH; Bae BG; Lee HJ; Lee MG; Lee KH
Exp Dermatol; 2010 Mar; 19(3):246-51. PubMed ID: 19758316
[TBL] [Abstract][Full Text] [Related]
8. Allergen immunotherapy for atopic dermatitis: Systematic review and meta-analysis of benefits and harms.
Yepes-Nuñez JJ; Guyatt GH; Gómez-Escobar LG; Pérez-Herrera LC; Chu AWL; Ceccaci R; Acosta-Madiedo AS; Wen A; Moreno-López S; MacDonald M; Barrios M; Chu X; Islam N; Gao Y; Wong MM; Couban R; Garcia E; Chapman E; Oykhman P; Chen L; Winders T; Asiniwasis RN; Boguniewicz M; De Benedetto A; Ellison K; Frazier WT; Greenhawt M; Huynh J; Kim E; LeBovidge J; Lind ML; Lio P; Martin SA; O'Brien M; Ong PY; Silverberg JI; Spergel J; Wang J; Wheeler KE; Schneider L; Chu DK
J Allergy Clin Immunol; 2023 Jan; 151(1):147-158. PubMed ID: 36191689
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of two commercial house dust mite extracts for allergic rhinitis: a head-to-head study.
Li J; Wu Y; Yang Y; Huang N; Li W; Zhang S; Jiang Q; Yang L; Zhu R
Int Forum Allergy Rhinol; 2019 Aug; 9(8):876-882. PubMed ID: 31322838
[TBL] [Abstract][Full Text] [Related]
10. Different Responses in Induction of Allergen Specific Immunoglobulin G4 and IgE-Blocking Factors for Three Mite Subcutaneous Immunotherapy Products.
Park KH; Lee SC; Son YW; Jeong KY; Shin YS; Shin JU; Sim da W; Park HJ; Lee JH; Lee KH; Park JW
Yonsei Med J; 2016 Nov; 57(6):1427-34. PubMed ID: 27593871
[TBL] [Abstract][Full Text] [Related]
11. Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial.
Eifan AO; Akkoc T; Yildiz A; Keles S; Ozdemir C; Bahceciler NN; Barlan IB
Clin Exp Allergy; 2010 Jun; 40(6):922-32. PubMed ID: 20100188
[TBL] [Abstract][Full Text] [Related]
12. Effect of one-year subcutaneous and sublingual immunotherapy on clinical and laboratory parameters in children with rhinitis and asthma: a randomized, placebo-controlled, double-blind, double-dummy study.
Yukselen A; Kendirli SG; Yilmaz M; Altintas DU; Karakoc GB
Int Arch Allergy Immunol; 2012; 157(3):288-98. PubMed ID: 22041501
[TBL] [Abstract][Full Text] [Related]
13. Clinical Response to Subcutaneous Dermatophagoides pteronyssinus Immunotherapy in Children with Allergic Rhinitis and Asthma Is Independent of Sensitization to Blomia tropicalis Allergens.
Chen S; Zheng Y; Chen B; Zhong H; Liao F; Wang L; Hui SF; Lai X
Int Arch Allergy Immunol; 2019; 178(2):201-210. PubMed ID: 30544116
[TBL] [Abstract][Full Text] [Related]
14. Subcutaneous immunotherapy with purified Der p1 and 2 suppresses type 2 immunity in a murine asthma model.
Hesse L; van Ieperen N; Habraken C; Petersen AH; Korn S; Smilda T; Goedewaagen B; Ruiters MH; van der Graaf AC; Nawijn MC
Allergy; 2018 Apr; 73(4):862-874. PubMed ID: 29318623
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of House Dust Mite Sublingual Immunotherapy in Patients with Atopic Dermatitis: A Randomized, Double-Blind, Placebo-Controlled Trial.
Langer SS; Cardili RN; Melo JML; Ferriani MPL; Moreno AS; Dias MM; Bueno-Filho R; Pocente RHC; Roxo-Junior P; Silva J; Valera FCP; Coelho EB; Galvão CES; Carmona F; Aragon DC; Arruda LK
J Allergy Clin Immunol Pract; 2022 Feb; 10(2):539-549.e7. PubMed ID: 34767999
[TBL] [Abstract][Full Text] [Related]
16. Immunoglobulin G1 subclass responses can be used to detect specific allergy to the house dust mites Dermatophagoides farinae and Dermatophagoides pteronyssinus in atopic dogs.
Khantavee N; Chanthick C; Tungtrongchitr A; Techakriengkrai N; Suradhat S; Sookrung N; Roytrakul S; Prapasarakul N
BMC Vet Res; 2021 Feb; 17(1):71. PubMed ID: 33546688
[TBL] [Abstract][Full Text] [Related]
17. The IgE Blocking Activity Induced by Dermatophagoides pteronyssinus Subcutaneous Immunotherapy Does Not Correlate with Specific IgA but with IgG4 in both Serum and Saliva.
He Y; Liu J; Zhao D; Zhang S; Hao G; Sun Y; Zhong H; Chen H; Würtzen PA; Larsen JN; Lai X
Int Arch Allergy Immunol; 2021; 182(12):1231-1244. PubMed ID: 34280916
[TBL] [Abstract][Full Text] [Related]
18. The indoor level of house dust mite allergen is associated with severity of atopic dermatitis in children.
Kim J; Lee S; Woo SY; Han Y; Lee JH; Lee IY; Lim IS; Choi ES; Choi BW; Cheong HK; Lee SI; Ahn K
J Korean Med Sci; 2013 Jan; 28(1):74-9. PubMed ID: 23341715
[TBL] [Abstract][Full Text] [Related]
19. [Safety of subcutaneous immunotherapy with tyrosine-adsorbed house dust mite extracts in patients with allergic disease].
Molina-Sáenz MM; Villa-Arango AM; Cardona-Villa R
Rev Alerg Mex; 2017; 64(1):52-65. PubMed ID: 28188713
[TBL] [Abstract][Full Text] [Related]
20. Retrospective Analysis on the Effects of House Dust Mite Specific Immunotherapy for More Than 3 Years in Atopic Dermatitis.
Lee J; Lee H; Noh S; Bae BG; Shin JU; Park CO; Lee KH
Yonsei Med J; 2016 Mar; 57(2):393-8. PubMed ID: 26847292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
